Dr. Shallis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
20 York St
New Haven, CT 06510Phone+1 203-688-4242Fax+1 203-785-4116
Education & Training
- Rutgers Robert Wood Johnson Medical SchoolClass of 2014
Certifications & Licensure
- CT State Medical License 2017 - 2025
- RI State Medical License 2014 - 2017
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Clinical Trials
- Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm Start of enrollment: 2023 Jun 27
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Cost-effectiveness of Enasidenib versus conventional care for older patients withmutant refractory/relapsed AML.Abdulrahman Alhajahjeh, Kishan K Patel, Rory M Shallis, Nikolai A Podoltsev, Tariq Kewan
Leukemia & Lymphoma. 2025-03-01 - Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy.Reid Shaw, James J Yoon, Hannah Johnston, Marta B Davidson, Alexa J Siddon
Blood Advances. 2025-02-19 - Evaluating the impact of stratification on the power and cross-arm balance of randomized phase 2 clinical trials.Anna Moseley, Michael LeBlanc, Boris Freidlin, Rory M Shallis, Amer M Zeidan
Clinical Trials. 2025-01-15
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: